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to liver injury and fibrosis suggesting the beneficial role of intestinal microbiota
in preventing liver injury1, 2.
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Introduction: Non-alcoholic fatty liver disease (NAFLD) pathogenesis and treat-
ment remain unsolved. microRNAs and bile acids were recently suggested to
participate in disease pathogenesis and, as such, constitute potential therapeutic
tools and targets. Moreover, nuclear receptors, namely peroxisome proliferator-
activated receptors (PPARs) and the farnesoid X receptor (FXR) are currently
under scrutiny as modulators of lipid and glucose metabolism in non-alcoholic
steatohepatitis (NASH).
Aims & Methods: We aimed to elucidate the role of the miR-21/PPAR pathway
in liver and muscle tissues of murine NASH models and ascertain the therapeutic
potential of miR-21 abrogation alone or in combination with obeticholic acid
(OCA). Wild-type (WT) and miR-21 KO mice were fed with chow (n¼ 10) or
methionine and choline-deficient (MCD; n¼ 10) diets for 2 and 8 weeks.
Alternatively, mice were fed either chow (n¼ 12) or fast food diet (FF; n¼ 12)
for 25 weeks. Six animals from each group had their diet supplemented with
OCA 10mg/kg/day (Intercept Pharmaceuticals, Inc.). Human liver biopsies
were obtained from morbid obese NAFLD patients (n¼ 28). Liver/muscle sam-
ples were processed for histological analysis and assessment of miR-21, pro-
inflammatory/pro-fibrogenic cytokines, PPAR and metabolic relevant genes,
by qRT-PCR and immunoblotting. A Taqman Array was performed to eval-
uate modulation of lipid regulated genes. ROS levels were analysed through the
use of 2’,7’- dichlorodihydrofluorescein diacetate.
Results: WT mice fed with the MCD diet developed steatohepatitis and fibrosis,
displaying increased levels of apoptosis, necroptosis and serum ALT and AST. In
contrast, miR-21 KO mice displayed a significant decrease in steatosis severity,
liver damage, inflammation and did not develop fibrosis. WT FF-fed mice devel-
oped hepatomegaly, macrovesicular steatosis, inflammatory infiltrates and
increased oxidative stress. miR-21 levels were increased in WT FF-fed mice, in
both liver and muscle, concomitantly with decreased expression of PPAR, a key
miR-21 target. Similar findings were observed in NAFLD patients. Further, WT
FFþOCA-fed mice exhibited decreased steatosis and miR-21 expression, com-
pared with WT FF-fed mice. Importantly, KO FFþOCA-fed mice exhibited
significantly reduced liver inflammation, oxidative stress and steatosis, in parallel
with increased expression of PPAR and its metabolic targets, including CPT-1
and ACOX2. Finally, lipid regulated genes such as ACAT1, ALOX5 and FABP5
were found to be severely deregulated in WT FF-fed mice and reverted to control
levels in KO FFþOCA-fed mice.
Conclusion: In conclusion, activation of PPAR, as a result of miR-21 abroga-
tion, together with FXR activation by OCA, significantly improves metabolic
parameters in NASH, highlighting the therapeutic potential of multi-targeting
therapies for NAFLD. (Supported by PTDC/BIM-MEC/0873/2012, SFRH/BD/
88212/2012, FCT, Portugal).
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Introduction: Presence of the single nucleotide polymorphism (SNP) rs2476601 in
the gene encoding protein tyrosine phosphatase non-receptor type 22 (PTPN22)
results in an altered-function PTPN22 protein product and is associated with
increased risk to develop autoimmune disorders, including type 1 diabetes, rheu-
matoid arthritis, systemic lupus erythematous. However, the same variant
reduces the risk for Crohn’s disease (CD) onset. We have previously shown
that protein and mRNA levels of PTPN22 are reduced in intestinal biopsies
from CD patients, and that loss of PTPN22 results in enhanced inflammatory
cytokine secretion from mononuclear cells treated with interferon-gamma or the
bacterial product muramyl dipeptide.
Aims & Methods: In this study, we addressed how presence of the altered-func-
tion variant in PTPN22 influences the susceptibility to intestinal inflammation in
mouse models of colitis. For this aim, colitis was induced in 10–12 week old
female mice by administration of 2% DSS for 7 days (acute DSS colitis), admin-
istration of four cycles of DSS (1.5% DSS for 7 days, followed by 10 days normal
drinking water each; chronic DSS colitis), or by transferring naı̈ve T cells into
RAG2-/- recipients. PTPN22 deficient (PTPN22-/-) mice, or mice expressing the
IBD-associated variant in PTPN22 (PTPN22-619W mice), and their respective
wild-type (WT) littermates were used for the study.
Result: PTPN22-/- mice suffered from aggravated acute DSS colitis as character-
ized by pronounced weight loss, increased endoscopic and histologic colitis scores
(p5 0.05 each), while PTPN22-619W mice reacted only weak to the DSS treat-
ment when compared to WT littermates (p5 0.05 for weigh development,
p5 0.01 for other parameters). In chronic DSS colitis however, PTPN22-/-
mice suffered from a milder disease course (reduced weight loss [p5 0.05],
decreased histological severity [p5 0.05]) from the third cycle onwards.
PTPN22-619W on the other hand mice tended to show a more pronounced
disease course in the later phase. In the T cell transfer model, PTPN22-/- T
cells induced an enhanced histological pathology (p5 0.05), while weight loss
was not affected when compared to mice receiving WT T cells. In contrast, mice
transfected with PTPN22-619W T cells were protected from disease development
in the first weeks, and later on developed only a mild disease (moderate weight
loss [p5 0.01], reduced shortening of the colon [p5 0.05], low histological dis-
ease scores [p5 0.05]) when compared to mice receiving WT T cells.
Conclusion: Taken together, we here describe for the first time how the IBD-
associated variant in PTPN22 affects colitis development. This helps to explain
why this variant is associated with a reduced risk for CD onset, although it
increases the risk to develop classical autoimmune disorders.
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Introduction: The recognition of intestinal microbiota is in part carried out by
toll-like receptors (TLR), which are responsible for initiating the innate immune
response. Alterations in the intestinal microbiota and its recognition may con-
tribute to the development of intestinal inflammatory pathologies. Otherwise,
hydrogen sulphide (H2S) is an endogenous gaseous signalling molecule and it
potentially plays a relevant role in the intestinal motility. In mammals, two
pyridoxalphosphate-dependent enzymes are responsible for H2S synthesis:
cystathionine b-synthase (CBS) and cystathionine -lyase (CSE).
Aims & Methods: The aim of this study was to investigate the influence of TLR2
on the motor response induced by H2S and the enzymes responsible for H2S
synthesis (CBS and CSE) in mouse colon. Colon strips from male C57/BL10
wild-type (WT) and TLR2-/- mice of 8–12 weeks old were suspended in an
organ bath in the direction of circular smooth muscle. We studied the effect of
NaHS (10 mM–1mM), D,L-propargylglycine (PAG, 10 mm–10mM), an inhibitor
of CSE, and amino-oxyacetic acid (AOAA, 10mm–10mM), an inhibitor of CBS,
on WT and TLR2-/- mice colonic motility. Gene expression (mRNA) of CSE and
CBS were determined by real time-PCR and protein expression of CSE and CBS
were quantified by Western blotting in colon from WT and TLR2-/- mice.
Results: The NaHS, as a source of exogenous H2S, reduced the frequency but not
the amplitude of the spontaneous contractions in colon from WT mice. The
inhibition of CSE or CBS with PAG or AOAA, respectively, increased the fre-
quency but not the amplitude of the spontaneous contractions in colon from WT
mice. The NaHS induced a higher reduction of the frequency of the spontaneous
contractions in TLR2-/- respect to WT mice. The PAG and AOAA did not
modify the spontaneous contractions in colon from TLR2-/- mice. The mRNA
and protein expression of CBS resulted decreased in colon of TLR2-/- compared
with WT mice. The mRNA but not the protein expression of CSE resulted
decreased in TLR2-/- compared with WT mice.
Conclusion: These results suggest that exogenous and endogenous H2S may reg-
ulate the colonic spontaneous contractions in WT mouse, reinforcing the hypoth-
esis that H2S is a gaseous inhibitory mediator of intestinal motility. TLR2
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regulates the expression of CBS and modulates the inhibitory motor response
induced by H2S in mouse colon.
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Introduction: Biologics targeting inflammatory cytokines has reveal a new era in
inflammatory bowel disease treatment. High mobility group protein B1
(HMGB1) acts as an alarmin in early stage and inflammatory cytokine in late
stage during inflammation. Direct blockade of HMGB1 can be protective against
intestinal inflammation.
Aims &Methods: Potential role of anti-HMGB1 neutralizing antibody (HnAb) in
inhibiting intestinal inflammation and the underlying mechanism is investigated
in DSS-induced mice colitis (DSS-C) models. 200mg HnAb was administrated
intraperitoneally to DSS-C at d0, d3 and d6 in HnAb group, whereas 200mg anti-
IgY was used as control in DSS-C (DSS-C group) or normal control (ctrl group).
Colon shortening, disease activity index (DAI), histological score of colitis (HS),
MPO activity and inflammatory cytokines were evaluated to determine the colo-
nic inflammation severity. Mucosa barrier function was assessed by immuno-
fluorescent staining of mucus layer (mucin2) and tight-junction (T-J) protein
detection. mRNA was detected by qPCR. T-J protein, HMGB1, TLR4,
MyD88 was detected by Western blotting and measured by Grey-scale value.
Statistical analysis was performed using one-way ANOVA analysis and the Post
Hoc LSD test or Tamhane’s T2 test.
Results: Treatment with HnAb significantly suppressed colonic inflammation in
DSS-C mice by improving colon shortening (6.2 0.4 cm vs. 5.3 0.5 cm,
p5 0.05), DAI (2.7 0.5 vs. 3.7 0.3, p5 0.05) and HS (6.0 0.1 vs.
9.6 0.7, p5 0.05). Besides, MPO activity (2.6 0.8 vs. 4.8 1.0, p5 0.05)
and TNF- (1.61 0.05 vs. 3.04 0.11, p5 0.05), IFN- (2.14 0.06 vs.
7.87 0.21, p5 0.05) and IL-1b (1.53 0.10 vs. 2.48 0.04, p5 0.05) mRNA
expression was decreased when treated with HnAb as compared to DSS-C group
(mRNA in ctrl group was set to 1). Relatively intact mucus layer was seen in mice
colon of HnAb group as compare to DSS-C group. Significantly higher expres-
sion of tight-junction protein ZO-1 (0.38 0.01 vs. 0.15 0.05, p5 0.0001), clau-
din-5 (0.50 0.09 vs. 0.17 0.07, p5 0.0001) and occludin (0.85 0.09 vs.
0.39 0.01, p5 0.0001) was detected in HnAb mice as compared to mice in
DSS-C group. Interestingly, colonic HMGB1 protein in both nucleus
(0.58 0.02 vs. 0.79 0.03, p5 0.0001) and cytoplasm (0.23 0.01 vs.
0.40 0.03, p5 0.0001) were all decreased when treated with HnAb as compare
to DSS-C, suggesting that primary inhibition of HMGB1 by HnAb blocked
sequential HMGB1 formation and release. Lastly, TLR4 (0.31 0.03 vs.
0.77 0.08, p5 0.0001) and MyD88 (0.30 0.03 vs. 0.78 0.01, p5 0.0001)
protein was significantly reduced in HnAb group than mice in DSS-C group
though MyD88 mRNA was relatively higher in HnAb group than DSS-C
group (0.69 0.04 vs. 0.38 0.01, p5 0.05).
Conclusion: Administration of HnAb ameliorated DSS-C by suppressing inflam-
mation and strengthening mucosa barrier function possibly through inhibition of
HMGB1-TLR4-MyD88 pathway, suggesting a potential interventional target of
HMGB1 in ulcerative colitis treatment.
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Introduction: PETIR (PEptidase-Targeted ImunoRegulation) is a novel therapeu-
tic strategy which takes for the purpose restoration of the immune balance by
limiting the activation of immune cells and induction of endogenous protective
mechanisms, such as TGFb and glucagon-like peptide-2 (GLP-2) through inhibi-
tion of DPP IV-dependent pathways. Experimental data indicate that PETIR
results in suppression of cell proliferation and reduced synthesis of pro-inflam-
matory cytokines without affecting cellular vitality.
Aims & Methods: The objective of this study was to test the anti-inflammatory
activity of a novel DPP IV inhibitor EMDB-1 in the mouse models of colitis. The
inhibitory effect of EMDB-1 on DPP IV was characterized in vitro using the
HPLC system measuring the degradation rate of endomorphin-2 (EM2, natural
DPP IV substrate) in the presence of the test compound. Anti-inflammatory
activity of EMDB-1 was investigated in the model of acute and semi-chronic
colitis induced by trinitrobenzenesulfonic acid (TNBS). Body weight, macro-
scopic score, ulcer score, colon length and thickness, as well as myeloperoxidase
(MPO) activity were recorded. Mesalazine was used as a reference drug.
Results: EMDB-1 is a potent and specific DPP IV inhibitor as shown by signifi-
cantly decreased degradation rate of EM2 by DPP IV (t0.5¼ 1.73 vs. 3.60min in
the absence and the presence of EMDB-1, respectively). The intracolonic (i.c.)
administration of EMDB-1 (0.1, 1 and 3mg/kg, twice daily) attenuated both
acute and semi-chronic TNBS-induced colitis in mice in a dose-dependent
manner, as indicated by significantly reduced macroscopic parameters and
MPO activity. Anti-inflammatory effect of EMDB-1 was not blocked by nalox-
one, thus the opioid receptors are not involved in its mechanism of action.
Conclusion: EMDB-1 is a potent inhibitor of DPP IV in vitro and exhibits sub-
stantial anti-inflammatory activity in the GI tract in vivo. Results of this study
validate the EMDB-1 backbone for further development of peptide DPP IV
inhibitors and suggest their potential use in the treatment of colitis.
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Introduction: Macrophages play a major role in inflammatory bowel disease
(IBD) pathogenesis through an inappropriate response to migration, and an
impaired transition from a pro-inflammatory (classical activated macrophages
(CAMs)) to an anti-inflammatory (alternative activated macrophages (AAMs))
phenotype. While there is growing awareness of a relationship between
Chromogranin (Cg)-A and a susceptibility to inflammatory conditions, the spe-
cific interaction between CgA-derived peptides and macrophage plasticity in IBD
is unknown. Recently, we have shown a linear correlation between CgA and
inflammatory markers in patients with active ulcerative colitis, and colitic
CgA-deficient mice demonstrated a significant decrease of colitis associated to
a modulation of macrophage activation. As Cg-A is a prohormone, herein, we
assessed the functional role of a specific CgA-derived peptides (Chromofungin
(CHR): hCg-A47-66) in the regulation of acute colitis and the functional plasti-
city of murine macrophages.
Aims & Methods: Colitis was induced in C57BL/6 mice (7–8 weeks old) by
administrating dextran sulfate sodium (DSS 5%) in drinking water for 5 days.
Preventive CHR (2.5mg/kg/day) or vehicle treatments started 1 day before
induction of colitis and lasted for a total of 6 days. Disease activity index
(DAI) was evaluated daily and mice were sacrificed on day 5 post-DSS induction
to assess the extent of colitis. At sacrifice macroscopic scores were evaluated,
serum level of C-reactive protein (CRP) was quantified using ELISA, and colonic
interleukin (IL)-1b, IL-6, TNF-, MIP-1, MIP-1b, and ARG-1 were assessed
using ELISA and RT-qPCR. Naı̈ve peritoneal macrophages were isolated from
non-colitic C57BL/6 mice and treated by CHR (200 ng/ml) then exposed for 6 h
to LPS (100 ng/ml) to promote CAMs, or to IL-4/IL-13 (20 ng/ml) to promote
AAMs. CAMs markers (IL-6, IL-1b, TNF-, MIP-1 & MIP-b) and AAMs
markers (ARG-1) were quantified by using ELISA and RT-qPCR.
Results: Preventive treatment with CHR significantly reduced the DAI onset and
severity of colitis associated to rectal bleeding, stool consistency and weight loss.
Macroscopic scores, serum-CRP, colonic IL-1b, IL-6, TNF-, MIP-1, MIP-1b
were significantly decreased, while ARG-1 was significantly increased. In vitro,
CHR-conditioned CAMS expressed significantly less IL-1b, IL-6, TNF-, MIP-
1, MIP-b, but, surprisingly, more ARG-1 when compared to LPS control con-
dition. Moreover, CHR-conditioned AMS expressed significantly more ARG-1
when compared to IL-4/IL-13 control condition.
Conclusion: These findings suggest that CHR can modulate the severity of experi-
mental colitis. CHR treatment can attenuate the severity of experimental colitis
and the inflammatory process via the modulation of the functional plasticity of
murine macrophages and their functions. Targeting CgA-derived peptides may
lead to novel therapeutic strategies in ulcerative colitis.
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